Core Viewpoint - The biopharmaceutical sector in China is experiencing a positive trend in innovation and investment, with significant growth in the approval of innovative drugs and a recovery in market conditions [1][2] Industry Summary - As of September 8, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.89%, with notable gains from companies such as United Imaging Healthcare (688271) up 11.48% and BGI Genomics (688114) up 9.35% [1] - The "National Drug Safety Publicity Week" launched on September 1 highlights the positive development of the pharmaceutical industry, with 210 innovative drugs approved in the past five years, indicating a sustained growth trend [1] - Currently, approximately 30% of the world's innovative drugs under research are from China, showcasing the country's significant role in global pharmaceutical innovation [1] Company Summary - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index as of August 29, 2025, include United Imaging Healthcare (688271), BeiGene (688235), and others, collectively accounting for 50.27% of the index [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the Sci-Tech Innovation Board Biopharmaceutical Index, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Board [2]

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 2025 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北 京诺禾致源科技股份有限公司（以下简称"诺禾致源"或"公司"）向特定对 象发行股票并上市项目的保荐人，据《证券发行上市保荐业务管理办法》、 《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续督导 职责，并出具本持续督导半年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场检查 的工作要求。 2、保荐人已与公司签订承销保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展持续 督导工作，并于 2025 年 8 月 8 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督导职 责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度； （3）查阅公司信息披露文件，查阅公司与关联方的 ...

Group 1 - The company announced the resignation of non-independent director Wang Qifeng due to adjustments in the corporate governance structure, but he will continue to work at the company [1][3] - Wang Qifeng was elected as the employee representative director during the company's second employee representative assembly held on September 1, 2025, with a term aligned with the fourth board of directors [1][4] - The resignation of Wang Qifeng will not affect the normal operation of the board or the company's daily operations, as it does not reduce the board members below the legal minimum [3][5] Group 2 - The company held its third meeting of the fourth board of directors on September 1, 2025, where members of the strategic committee and the remuneration and assessment committee were elected [2][6] - The remuneration and assessment committee consists of a majority of independent directors, with an independent director serving as the chairperson [6][7] - The term for the newly elected committee members will last until the end of the fourth board's term [6][7] Group 3 - The company convened its first extraordinary general meeting of shareholders on September 1, 2025, where all proposed resolutions were approved without any being rejected [8][9] - The meeting was conducted in compliance with relevant laws and regulations, with all board members and the board secretary present [10][11] - The resolutions included the cancellation of the supervisory board and amendments to the company's articles of association, which were passed with the required majority [10][11]

Group 1 - The company, Novogene, announced the convening of its first extraordinary general meeting of shareholders for 2025 on September 1, 2025 [2] - The meeting will review and approve the proposal regarding the revision and formulation of certain corporate governance systems [2]

Core Viewpoint - The company announced the election of Mr. Wang Qifeng as the employee director of the fourth board of directors during the employee representative meeting held on September 1, 2025 [1] Group 1 - The employee representative meeting took place on September 1, 2025 [1] - Mr. Wang Qifeng was elected as the employee director by all attending employee representatives [1]

Group 1 - The legal opinion letter is issued by Beijing Zhonglun Law Firm regarding the legality of the 2025 first extraordinary general meeting of shareholders of Beijing Novogene Bioinformatics Technology Co., Ltd [1][2] - The law firm confirms that it has reviewed the necessary documents and materials provided by the company for the issuance of the legal opinion [2][4] - The legal opinion focuses on the convening, holding procedures, qualifications of attendees, and voting procedures of the shareholders' meeting, without commenting on the content of the proposals discussed [4][9] Group 2 - The notice for the shareholders' meeting was properly communicated to all shareholders, including details on time, location, agenda, and registration methods [5][6] - The meeting was held at Novogene Building, with the chairman presiding, and voting was conducted both on-site and via an online platform [6][9] - A total of 2 shareholders attended the meeting in person, representing 214,810,348 shares, and 61 shareholders participated through online voting [6][7] Group 3 - The voting results showed that 218,029,592 shares were in favor of the proposals, with a small number of shares abstaining [9] - The law firm concludes that the convening, holding procedures, qualifications of attendees, and voting results of the shareholders' meeting are all in compliance with relevant laws and regulations [9]

Meeting Overview - The shareholder meeting was held on September 1, 2025, at the company's headquarters in Beijing [1] - A total of 63 ordinary shareholders attended, holding 218,106,509 voting rights, which represents 53.8457% of the company's total voting rights [1] Voting Process - The meeting was conducted in accordance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [1] - The meeting was chaired by the company's chairman, Mr. Li Ruiqiang, and attended by directors and supervisors [1] Resolution Results - The first resolution, a special resolution, was passed with over two-thirds of the voting rights in favor [1] - The second resolution was passed with 98.8901% of the votes in favor, indicating strong shareholder support [1] Legal Compliance - The meeting's procedures and voting results were confirmed to be in compliance with relevant laws and regulations, ensuring the legitimacy of the proceedings [2]

Core Points - The announcement details the resignation of non-independent director Wang Qifeng and his subsequent election as an employee representative director [1][4] - The company held its second employee representative meeting on September 1, 2025, where Wang Qifeng was elected to the fourth board of directors [1][5] - The board also convened its third meeting on the same day to elect members for the strategic committee and the compensation and assessment committee [2][5] Director Resignation - Wang Qifeng resigned from his position as a non-independent director on September 1, 2025, due to adjustments in the company's governance structure [1][3] - His resignation does not affect the minimum number of board members required by law, and it will not impact the company's normal operations [3][4] Employee Director Election - Following Wang Qifeng's resignation, he was elected as an employee director during the employee representative meeting, with his term aligning with the fourth board's term [1][5] - The election ensures that the number of employee representatives on the board does not exceed half of the total board members, complying with relevant regulations [5] Board Committee Adjustments - The third meeting of the fourth board resulted in the election of members for the strategic committee and the compensation and assessment committee [2][5] - The strategic committee is composed of Li Ruiqiang, Wang Qifeng, and Gan Quan, while the compensation and assessment committee includes Wang Chunfei, Wang Tianfan, and Wang Qifeng [5]

证券代码：688315 证券简称：诺禾致源 公告编号：2025-036 北京诺禾致源科技股份有限公司 关于公司非独立董事离任暨选举职工董事 及调整第四届董事会专门委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京诺禾致源科技股份有限公司（以下简称"公司"）董事会于近日收到公 司非独立董事王其锋先生的书面辞职报告。因公司治理结构的调整，王其锋先生 申请辞去公司董事职务及董事会下设专门委员会相应职务。辞去上述职务后，王 其锋先生仍在公司任职。根据《中华人民共和国公司法》《公司章程》的有关规 定，王其锋先生的辞职不会导致公司董事会成员低于法定最低人数，其辞职报告 自送达董事会时生效。 | | | (二) 离任对公司的影响 公司于 2025 年 9 月 1 日召开了 2025 年第二次职工代表大会，选举王其锋先 生担任公司第四届董事会职工代表董事，任期与公司 2024 年年度股东大会选举 产生的第四届董事会董事任期一致。 公司于 2025 年 9 月 1 日召开了第四届董事会第三次会议，选举产生 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-037 北京诺禾致源科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 63 | | --- | --- | | 普通股股东人数 | 63 | | 2、出席会议的股东所持有的表决权数量 | 218,106,509 | | 普通股股东所持有表决权数量 | 218,106,509 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 53.8457 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 53.8457 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 1 日 （二） 股东 ...